Canada Pension Plan Investment Board Invests $330,000 in Ultragenyx Pharmaceutical Inc. (RARE)

Canada Pension Plan Investment Board purchased a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 6,200 shares of the biopharmaceutical company’s stock, valued at approximately $330,000.

Other large investors have also recently bought and sold shares of the company. Pictet Asset Management Ltd. raised its position in Ultragenyx Pharmaceutical by 27.4% in the third quarter. Pictet Asset Management Ltd. now owns 750,407 shares of the biopharmaceutical company’s stock worth $39,967,000 after acquiring an additional 161,196 shares during the period. First Trust Advisors LP raised its position in shares of Ultragenyx Pharmaceutical by 2.8% during the 3rd quarter. First Trust Advisors LP now owns 525,878 shares of the biopharmaceutical company’s stock valued at $28,008,000 after purchasing an additional 14,138 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $213,000. Ameritas Investment Partners Inc. raised its position in shares of Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 248 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,864 shares of the biopharmaceutical company’s stock valued at $1,917,000 after purchasing an additional 2,212 shares during the period. Hedge funds and other institutional investors own 94.13% of the company’s stock.

A number of analysts have issued reports on the stock. Evercore ISI assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 16th. They issued an “in-line” rating and a $63.00 price target on the stock. Morgan Stanley reissued an “equal weight” rating and issued a $69.00 price objective (down from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $85.00 price objective (down from $95.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 price target (down from $89.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Finally, Cowen reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $72.40.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded down $2.61 during midday trading on Thursday, reaching $46.17. 566,419 shares of the company were exchanged, compared to its average volume of 438,951. Ultragenyx Pharmaceutical Inc. has a 12-month low of $44.02 and a 12-month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. The business’s revenue was up 81.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.64) earnings per share. analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -7.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/07/canada-pension-plan-investment-board-invests-330000-in-ultragenyx-pharmaceutical-inc-rare.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply